金复康口服液对气阴两虚型非小细胞肺癌患者的疗效和血清MMP-9水平的影响
|
摘要
目的:研究金复康口服液联合吉西他滨对气阴两虚型非小细胞肺癌患者的疗效和血清MMP-9水平的影响。方法:选取符合纳入标准的120例气阴两虚型非小细胞肺癌患者作为研究对象,随机分为对照组和治疗组,每组60例。对照组给予吉西他滨,治疗组给予金复康口服液联合吉西他滨。比较两组患者临床疗效、血压情况、雌激素水平和不良反应发生情况。结果:治疗后,治疗组的有效率和临床获益率显著高于对照组,差异具有统计学意义(P <0. 05);治疗组FACT-L评分下降率显著低于对照组,差异具有统计学意义(P <0. 05);治疗组中医证候有效率显著高于对照组,差异具有统计学意义(P <0. 05);两组患者MMP-9水平均显著优于治疗前,差异具有统计学意义(P <0. 05);且治疗组患者改善程度高于对照组,差异具有统计学意义(P <0. 05)。治疗组患者不良反应发生率显著低于对照组,差异具有统计学意义(P <0. 05)。结论:金复康口服液联合吉西他滨治疗气阴两虚型非小细胞肺癌,具有较好的治疗效果,并且能够改善患者生活质量和中医证候,安全性好,值得在临床上推广应用。
Objective: To study the effect of Jinfukang Oral Liquid combined with Gemcitabine on serum level of MMP-9 in non-small cell lung cancer patients with deficiency of both qi and yin. Methods: 120 patients with non-small cell lung cancer of deficiency of both qi and yin were randomly divided into the control group(n = 60) and observation group(n = 60). The control group was treated with Gemcitabine,whereas the observation group was treated with Jinfukang Oral Liquid combined with Gemcitabine. The clinical efficacy,blood pressure,estrogen level and adverse reactions were compared between the two groups. Results: After the treatment,the effective rate and clinical benefit rate of the observation group were significantly higher than those of the control group(P < 0. 05). The drop rate of FACT-L score in the observation group was significantly lower than that in the control group(P < 0. 05). The effective rate of TCM syndromes in the observation group was significantly higher than that in the control group(P < 0. 05). The level of MMP-9 was significantly improved after the treatment in the two groups(P < 0. 05); the improvement was more significant in the observation group than that in the control group(P < 0. 05). The incidence of adverse reactions was significantly lower in the observation group than that in the control group(P < 0. 05). Conclusion: Jinfukang Oral Liquid combined with Gemcitabine has better curative effect on non-small cell lung cancer with deficiency of both qi and yin,it can improve the life quality of the patients and TCM syndromes with its high safety,which is worthy of clinical application.
Objective: To study the effect of Jinfukang Oral Liquid combined with Gemcitabine on serum level of MMP-9 in non-small cell lung cancer patients with deficiency of both qi and yin. Methods: 120 patients with non-small cell lung cancer of deficiency of both qi and yin were randomly divided into the control group(n = 60) and observation group(n = 60). The control group was treated with Gemcitabine,whereas the observation group was treated with Jinfukang Oral Liquid combined with Gemcitabine. The clinical efficacy,blood pressure,estrogen level and adverse reactions were compared between the two groups. Results: After the treatment,the effective rate and clinical benefit rate of the observation group were significantly higher than those of the control group(P < 0. 05). The drop rate of FACT-L score in the observation group was significantly lower than that in the control group(P < 0. 05). The effective rate of TCM syndromes in the observation group was significantly higher than that in the control group(P < 0. 05). The level of MMP-9 was significantly improved after the treatment in the two groups(P < 0. 05); the improvement was more significant in the observation group than that in the control group(P < 0. 05). The incidence of adverse reactions was significantly lower in the observation group than that in the control group(P < 0. 05). Conclusion: Jinfukang Oral Liquid combined with Gemcitabine has better curative effect on non-small cell lung cancer with deficiency of both qi and yin,it can improve the life quality of the patients and TCM syndromes with its high safety,which is worthy of clinical application.
引文
[1]孙益锋,高文.老年非小细胞肺癌的治疗进展[J].老年医学与保健,2016,22(3):135-139.
[2]陈鹏程,毛伟敏.非小细胞肺癌的中西医治疗进展[J].中国临床保健杂志,2016,19(2):128-131.
[3]周红,高亚洲.康艾注射液联合吉西他滨治疗非小细胞肺癌的临床研究[J].现代药物与临床,2016,31(7):1050-1054.
[4]陈晓华,龚惠莉,邱晓平.唑来膦酸联合吉西他滨治疗非小细胞肺癌疗效观察[J].海南医学,2017,28(11):1744-1746.
[5]石红,刘杰,林洪生.中医药维持治疗晚期非小细胞肺癌的现状分析[J].临床肿瘤学杂志,2016,21(4):372-375.
[6]黄默菲.金复康口服液对气阴两虚型非小细胞肺癌患者抗肿瘤免疫反应的调节[D].上海:上海中医药大学,2016:1-10.
[7]马漪,曹建雄.养肺解毒汤治疗气阴两虚型非小细胞肺癌的临床研究[J].中医药导报,2017,23(24):31-33.
[8]杨新妹,徐玉芬,宋斌斌,等.益气化痰方联合化疗对晚期非小细胞肺癌患者临床疗效、不良反应以及生存质量的影响[J].中华中医药学刊,2016,34(5):1037-1039.
[9]梁平,辛海.益气养阴方配合化疗治疗老年晚期非小细胞肺癌40例临床观察[J].中医药导报,2016,22(1):30-32.
[10]彭东旭,方晓娟,杜均详,等.培美曲塞联合顺铂化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响[J].临床肺科杂志,2016,21(7):1306-1309.
[11]赵铎,高宝安.中晚期非小细胞肺癌联合治疗研究进展[J].海南医学,2016,27(3):438-441.
[12]张婧婧,赵庆伟,杨景瑞,等.吉西他滨对人非小细胞肺癌HCC827活性和凋亡的影响[J].中国免疫学杂志,2016,32(10):1450-1453.
[13]胡彬彬,陈宝清,卢铀.贝伐单抗治疗晚期非小细胞肺癌的疗效与安全性临床研究进展[J].中国肿瘤临床,2017,44(3):129-135.
[14]温珍平,韩雅玲.晚期非小细胞肺癌维持治疗进展[J].国际肿瘤学杂志,2016,43(2):148-151.
[15]蒋义鑫,徐元,周之毅,等.金复康口服液诱导肺癌细胞A549凋亡的机制[J].中国实验方剂学杂志,2018,24(9):160-165.
[16]方利洲,刘凌,张剑青,等.吉非替尼对中、晚期非小细胞肺癌患者血清MMP-7、MMP-9表达的影响[J].基因组学与应用生物学,2016,35(11):2909-2915.
[17]王国华,刘凤玲,张振山,等.参一胶囊联合化疗治疗晚期非小细胞肺癌疗效观察与血清MMP-9及TIMP-1变化[J].现代肿瘤医学,2017,25(6):896-901.
[18]赵艳莉,吴召利,千维娜,等.扶正益气抗癌汤联合化疗治疗晚期非小细胞肺癌对患者血清MMP-9、VEGF、T细胞亚群水平影响分析[J].现代中药研究与实践,2017,31(6):68-71.
[2]陈鹏程,毛伟敏.非小细胞肺癌的中西医治疗进展[J].中国临床保健杂志,2016,19(2):128-131.
[3]周红,高亚洲.康艾注射液联合吉西他滨治疗非小细胞肺癌的临床研究[J].现代药物与临床,2016,31(7):1050-1054.
[4]陈晓华,龚惠莉,邱晓平.唑来膦酸联合吉西他滨治疗非小细胞肺癌疗效观察[J].海南医学,2017,28(11):1744-1746.
[5]石红,刘杰,林洪生.中医药维持治疗晚期非小细胞肺癌的现状分析[J].临床肿瘤学杂志,2016,21(4):372-375.
[6]黄默菲.金复康口服液对气阴两虚型非小细胞肺癌患者抗肿瘤免疫反应的调节[D].上海:上海中医药大学,2016:1-10.
[7]马漪,曹建雄.养肺解毒汤治疗气阴两虚型非小细胞肺癌的临床研究[J].中医药导报,2017,23(24):31-33.
[8]杨新妹,徐玉芬,宋斌斌,等.益气化痰方联合化疗对晚期非小细胞肺癌患者临床疗效、不良反应以及生存质量的影响[J].中华中医药学刊,2016,34(5):1037-1039.
[9]梁平,辛海.益气养阴方配合化疗治疗老年晚期非小细胞肺癌40例临床观察[J].中医药导报,2016,22(1):30-32.
[10]彭东旭,方晓娟,杜均详,等.培美曲塞联合顺铂化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响[J].临床肺科杂志,2016,21(7):1306-1309.
[11]赵铎,高宝安.中晚期非小细胞肺癌联合治疗研究进展[J].海南医学,2016,27(3):438-441.
[12]张婧婧,赵庆伟,杨景瑞,等.吉西他滨对人非小细胞肺癌HCC827活性和凋亡的影响[J].中国免疫学杂志,2016,32(10):1450-1453.
[13]胡彬彬,陈宝清,卢铀.贝伐单抗治疗晚期非小细胞肺癌的疗效与安全性临床研究进展[J].中国肿瘤临床,2017,44(3):129-135.
[14]温珍平,韩雅玲.晚期非小细胞肺癌维持治疗进展[J].国际肿瘤学杂志,2016,43(2):148-151.
[15]蒋义鑫,徐元,周之毅,等.金复康口服液诱导肺癌细胞A549凋亡的机制[J].中国实验方剂学杂志,2018,24(9):160-165.
[16]方利洲,刘凌,张剑青,等.吉非替尼对中、晚期非小细胞肺癌患者血清MMP-7、MMP-9表达的影响[J].基因组学与应用生物学,2016,35(11):2909-2915.
[17]王国华,刘凤玲,张振山,等.参一胶囊联合化疗治疗晚期非小细胞肺癌疗效观察与血清MMP-9及TIMP-1变化[J].现代肿瘤医学,2017,25(6):896-901.
[18]赵艳莉,吴召利,千维娜,等.扶正益气抗癌汤联合化疗治疗晚期非小细胞肺癌对患者血清MMP-9、VEGF、T细胞亚群水平影响分析[J].现代中药研究与实践,2017,31(6):68-71.